That pharmacy trend will become apparent when they report earnings in the first half of the year. As to the ratings, we ve got five Strong Buys. It s one of the strongest players in the industry, selling at a discount to the group, which is unwarranted, and we believe that there is upside to our estimates. There are a couple of possibly significant events. We might see a Patient Bill of Rights go before the new Congress.
Any time there s a discussion about that issue, it makes investors nervous.
No one currently knows if they re going to pass this, but it s possible, so that s one risk. In Florida, there are a series of class-action lawsuits against the HMOs. They ve been consolidated in front of Judge Moreno in Miami, and he s going to rule whether those cases can move forward around the middle or the end of February. We believe that he s going to throw the cases out but you never know, and that s a risk. Those are the two biggest risks.